| HOME >> BIOLOGY >> TECHNOLOGY |
Payables due to distribution agreement
partners 44,885 36,479
Accrued salaries and employee benefits 8,807 16,596
Accrued expenses and other current liabilities 31,196 27,518
Total current liabilities 312,738 312,793
Long-term debt, less current portion - -
Other long-term liabilities 32,108 30,975
Commitments and contingencies - -
Stockholders' equity
Preferred Stock, par value $0.0001 per share,
authorized 6,000,000 shares; none issued and
outstanding - -
Common Stock, par value $0.01 per share,
authorized 90,000,000 shares; issued
37,187,155 and 36,460,461 shares 372 364
Additional paid-in capital 282,033 274,963
Retained earnings 212,718 230,195
Accumulated other comprehensive loss (1,235) (1,362)
Treasury stock, at cost 2,666,226 and
2,604,977 shares (67,604) (66,405)
Total stockholders' equity 426,284 437,755
Total liabilities and stockholders' equity $771,130 $781,523
PAR PHARMACEUTICAL COMPANIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Per Share Data)
(Unaudited)
Three Months Ended Six Months Ended
June 28, June 30, June 28, June 30,
2008 2007 2008 2007
<
'/>"/>
| SOURCE Par Pharmaceutical Companies, Inc. Copyright©2008 PR Newswire. All rights reserved |